I really believe that it doesnt matter in the end. I think they are most likely working on important stuff like sales, partnerships and getting other trials started, but yes, they could do a few little thing to help us out. I emailed them about it. Perhaps a few emails from investors suggesting the need to provide updates would be helpful. Below is the email I sent and the address if anyone else is interested.
"As a Protalix investor I feel a little disappointed that the only major news coming out of approval thus far has been that management has sold millions of dollars in shares of PLX. Are any updates as to a possible sales launch, sales force size, milestone payments, etc. planned at some point? Would be nice to hear something positive."
What's up is that we have a company that isn't "investor friendly".... which makes it exponentially tough, turns people like me off to find other opportunities with companies that see value in doing the "small things" to increase their awareness and market capitalization.
Ive been in PLX for a while now and I am a biotechie. I also think the sale is positive news. To see hundreds of thousands of sales with bad news looming would be illegal. My point is that in this biotech world there is a PR game and so many people play it well. PLX plays it horribly. And the only major news since approval has been that management is dumping shares. I agree thats not accurate, but I think that is how things look to many investors. In addition, I thik there are legitimate questions to be answered; i.e., are there milestones that we reached? are there payments on the way? ho much are those payments? when are sales expected to begin? outside of a 25% discount, is there a sales strategy? What kind of sales force is being dedicated to the task? I hear rumors about these on the MBs, but nothing seems certain and definitive. And, this info is not only pertinent, it is part of the game and 99.9% of other biotechs would have provided this info in a slew of PR by now, so whats up?